Current treatment of cutaneous leishmaniasis includes pentavalent antimonials as first-line
drugs, but this therapy has shown severe adverse effects. An alternative to minimize this …

Leishmaniasis is a disease caused by Leishmania spp., affecting millions of people around
the world. For decades, its treatment has been based on pentavalent antimonials, which …

Epoxymethoxy-lawsone is a naphthoquinone derivative promising as drug candidate for the
treatment of leishmaniases. In the present work the effectiveness of epoxymethoxylawsone …

The leishmanicidal activity of four batches of meglumine antimoniate, produced in
Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime® …

Pentavalent antimonial (SbV) is the first treatment for cutaneous leishmaniasis (CL). Other
drugs present similar side effects and higher cost. Oral miltefosine is effective to treat kala …

The identification of new therapeutics to treat leishmaniasis is desirable, since available
drugs are toxic and present high cost and/or poor availability. Therefore, the discovery of …

Leishmaniasis, a disease caused by parasites of the Leishmania genus, constitutes a
significant health and social problem in many countries and is increasing worldwide. The …

Leishmaniasis has become a significant public health issue in several countries in the world.
New products have been identified to treat against the disease; however, toxicity and/or high …

New therapeutic strategies against leishmaniasis are desirable, since the treatment against
disease presents problems, such as the toxicity, high cost and/or parasite resistance. As …

Leishmaniasis' treatment is based mostly on pentavalent antimonials or amphotericin B long-
term administration, expensive drugs associated with severe side effects. Considering these …